ArticlePituitary2015
Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.
Article in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.Journal of endocrinological investigation · 2022Pooled it
- Quality of life questionnaires in patients with acromegaly: a scoping review.Journal of patient-reported outcomes · 2026Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.Endocrine connections · 2024Article
- Pasireotide in the Personalized Treatment of Acromegaly.Frontiers in endocrinology · 2021Review
- Acromegaly in the elderly patients.Endocrine · 2020Review
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Pegvisomant in acromegaly: a multicenter real-life study in Argentina.Archives of endocrinology and metabolism · 2019Observational
- Brazilian multicenter study on pegvisomant treatment in acromegaly.Archives of endocrinology and metabolism · 2019Article
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- How to improve effectiveness of pegvisomant treatment in acromegalic patients.Journal of endocrinological investigation · 2018Observational
- Utility of baseline serum phosphorus levels for predicting remission in acromegaly patients.Journal of endocrinological investigation · 2017Article
- Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017Review
- Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.Pituitary · 2017Review
- Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.Archives of endocrinology and metabolism · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed at investigating predicting factors for therapy response under growth hormone receptor antagonist therapy with a focus on subjective and patient-oriented measures.
methodsObservational, multicenter nested-cohort study including 271 selected patients with the diagnosis of acromegaly and a minimum of one-year follow-up period within the German ACROSTUDY cohort (total cohort: n = 514). Outcome measures were the change of the biomarker IGF-1 (IGF-1 change and IGF-1 normalisation) between baseline and after 1 year of pegvisomant therapy (12 ± 6 months). Main predictors were patient-assessed subjective measures according to the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) in conjugation with age, gender, BMI, max. dosage of pegvisomant at follow-up and IGF-1 before the start of pegvisomant therapy.
resultsThe mean age of the study population was 51.2 (13.9) years and the mean BMI was 29.5 (5.1) kg/m(2). In adjusted analyses, none of the individual perceived health (PASQ) scores, but age, BMI and IGF-1 at baseline were predictive for an IGF-1 decrease after 1 year of pegvisomant therapy and BMI and IGF-1, but equally none of the PASQ items, were predicting IGF-1 normalisation.
conclusionsAge, BMI and baseline IGF-1 but not subjective perceived health measures predict therapy response under second line medical therapy with pegvisomant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.